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Abstract 
Retentive drug delivery systems are intended for prolonged residence and release inside 
hollow organs of the body, in pursuit of either local or systemic therapeutic goals. Because of 
the relatively long-lasting period of time they could cover during operation, a primary 
advantage arising from their use would lie in reduced dosing frequency, thereby improving the 
overall adherence of patients to prescribed medication regimens. The treatment of numerous 
pathologies that affect the urinary bladder and the stomach could especially benefit from 
viability of such delivery technologies. Moreover, by making use of effective gastroretentive 
dosage forms, the bioavailability of drugs that are preferably absorbed from the upper 
gastrointestinal tract could be increased. Expansion of devices following administration is often 
exploited for retention purposes, and several formulation strategies have been proposed in this 
respect. Innovative applications of shape memory materials have also been explored, 
highlighting the great inherent potential for facing the challenges involved.  
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Introduction 
In pharmaceutical care, the lack of adherence to prescribed administration regimens is 
widely known to negatively impact on the therapeutic outcome, having unfavorable 
repercussions on risk to benefit ratio and healthcare costs. Among therapy-related factors, the 
dosing frequency represents one of the main determinants of poor patient compliance1. This 
would particularly apply to chronic disease conditions involving lifelong medication or 
inconvenient modes and routes of administration, which will increasingly be the case in view 
of population aging and ever more numerous treatments based on biological drugs having 
unfavorable biopharmaceutical and pharmacokinetic properties. Thus, there is a strong rationale 
behind all efforts made to reduce the degree of complexity of dosing schedules. 
Drug delivery sciences are primarily concerned with supplying the patients' body with the 
right amount of the indicated bioactive molecules according to the most appropriate spatial and 
temporal patterns for meeting therapeutic needs that are being faced. Since its earliest days, 
research in this field has been endeavoring to tackle the issues raised by frequent dosing. As a 
result, prolonged-release dosage forms, able to make the bioactive molecule slowly available 
for absorption over an extended period of time, have been proposed in a large number and 
variety during the last fifty years, mainly with the aim of counteracting drug elimination half-
lives that would bind to more closely repeated administration. In several instances, such 
delivery systems, mostly intended for peroral or parenteral dosing, have been proved highly 
successful in lessening the burden brought about by pharmacological therapy. Particularly, 
advanced formulations meant for the oral route have led to once- or twice-daily dosing of 
bioactive compounds that would involve frequent daylong intake when given as immediate-
release dosage forms, thereby impacting heavily on living habits and posing a serious threat to 
adherence2. On the other hand, the use of injectable and implantable systems for prolonged drug 
release, which are not affected by the limited gastrointestinal residence time, has made infradian 
time spans between successive doses even possible, thus helping reduce dropouts due to pain 
and discomfort associated with invasive dosage. 
However, while prolongation of drug release over time through proper formulation strategies 
is invariably required for a reduced dosing frequency, it may alone be insufficient to address 
such issues. For instance, this might occur when it is necessary to establish persisting effective 
drug concentrations within a specific compartment of the body, often because a local action is 
sought and systemic exposure is deliberately prevented3. Otherwise, preferential entryways to 
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the systemic circulation, such as absorption windows in the upper gastrointestinal tract, may 
need to be exploited. In all of these cases, extended residence of the drug delivery system at the 
site of action or absorption would also be necessary. Accordingly, a more complex approach 
based on combined strategies or technologies has to be pursued in order to consistently slow 
down release of the bioactive compound(s) irrespective of the physiological variables 
encountered (volume, pH, ionic strength, composition and hydrodynamics of the medium, 
presence of enzymes, mucus etc.) and concomitantly maintain the delivery system in the desired 
anatomical position throughout a sufficiently long-lasting period of time. The intervals during 
which the resulting formulation would slowly deliver the active ingredient and reside inside the 
target compartment should roughly overlap. Moreover, they would have to cover the 
therapeutic time frame as completely as possible, or else be as extended as possible when 
chronic treatments are dealt with. 
Interestingly, such a combination approach may especially be beneficial to improve delivery 
of drugs to hollow muscular organs in the body. These are in the form of a sac made up of 
overlaid tissue layers, wherein a leaky inner cavity contains an aqueous biological fluid varying 
in volume and composition. The cavity is connected with the outer environment through single 
or multiple passageway ducts that fulfill diverse physiological functions and may be blocked 
up by sphincteric contraction. It ensues that, because the drug would fast be cleared from the 
interior of the sac as a solution or a dispersion, either by continuous or periodic emptying 
depending on sphincter activity, administration of simple immediate-release dosage forms 
would largely fail to provide the desired local concentrations during the time frame concerned. 
As a result, frequent and/or systemic dosing modes would have to be used to overcome the drug 
loss due to continuous washout. 
Regardless of how freely the cavities of hollow organs can be accessed for medication, the 
key point in the design and formulation of a system aimed at in situ delivery is that sizes 
differing from one another would be required for safe entry into and effective retention within 
them, respectively. On the one hand, a sufficiently small-sized conformation would indeed be 
needed for administration and positioning of the drug-loaded device inside the cavity, whereas, 
on the other, a larger spatial encumbrance would be mandatory for its untimely emptying to be 
prevented. Importantly, the bulky conformation could serve the purpose only if it were reached 
promptly after dosing and subsequently maintained over time also in spite of physical stresses 
undergone due to smooth muscle contractions. The dosage unit would thus be expected to 
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possess adequate mechanical resistance characteristics when taking on the cumbersome 
retentive configuration. Evolution from a smaller to a larger size may result from differing 
physical phenomena, such as water-swelling occurring on glass-rubber transition, osmotically-
induced water uptake or return to an originally bulkier shape, e.g. because of unfolding and/or 
elastic behavior upon discontinuation of a compressive external force, or else in view of 
inherent shape memory properties of component materials3–7. 
While a properly-designed intra-organ delivery system would help reduce the frequency of 
administration, thereby promoting the overall patient compliance, it is understood that it should 
not negatively impact on the latter when dosed to, retained in or retrieved from the release site. 
To this end, a number of additional requirements, strictly associated with regulatory safety 
prerequisites, have to be satisfied beyond the basic concepts of enduring residence and 
prolonged release performance within the organ of interest. Firstly, the delivery device should 
be suitable for painless and convenient administration modes. Moreover, every hazard that may 
arise from long-term location in the host body part needs to be ruled out. On operation, it is thus 
expected not to cause any harmful reactions, interfere with the physiological functions 
performed by the organ, bring about damages to the mucosa or the other tissues the wall is 
formed from, either at the micro- or macroscale level, alter motility patterns, ease microbial 
infection and proliferation, obstruct connection canals or orifice sphincters. Also, it should 
possibly be subject to spontaneous elimination processes after exhaustion, e.g. by dissolving, 
disintegrating, undergoing chemical degradation or collapsing. Otherwise, it should involve no 
painful and uncomfortable removal procedures. The total residence should be well 
characterized and consistent in duration, to overcome risks of longer-lasting contact of the organ 
with the foreign unit or even of accumulation thereof. 
The above-depicted scenario typically relates to hollow organs of the digestive and 
genitourinary systems, namely the stomach and the urinary bladder. In this respect, a wide range 
of tasks need to be accomplished by drug delivery sciences to properly face the many issues 
pending. The particular challenges posed by intragastric and intravesical administration of 
drugs have been identified and broadly discussed in the last decades, as major medical needs 
were being highlighted. Such aspects are reviewed hereby, along with those design strategies 
that leverage shape memory materials. These are endowed with the ability to retain memory of 
a permanent original shape and, after deformation into substantially different temporary shapes, 
recover it upon exposure to appropriate non-mechanical environmental stimuli8,9. Thanks to the 
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unique potential they hold, the use of shape memory materials for sophisticated biomedical and 
pharmaceutical applications is currently at the forefront of healthcare research and has opened 
up deeply innovative prospects in the field of retentive drug delivery devices10.  
 
Intravesical Delivery Systems 
The urinary bladder is a hollow muscular organ responsible for storage and disposal of urine 
coming from the kidneys via the ureters, which drains waste substances cleared from the 
systemic circulation11. The urethra connects the bladder cavity with the external urinary meatus. 
Shape, dimensions and relative position of the bladder vary as a function of the filling state and 
on the adjacent organs. It stretches and contracts continually as urine is collected and emptied, 
respectively. Capacity is reported to be of 400-600 mL and, under maximum filling conditions, 
pseudospherical shape is reached. The wall comprises a mucosal, a smooth muscle, i.e. the 
detrusor, and a serous layer. The mucosa epithelium, known as urothelium, is interfaced with 
the urinary fluid and, independent of the filling state, performs a critical function as an 
impermeable barrier, which is also enabled by the urothelial glycosaminoglycan (GAG) layer 
covering the typical umbrella cells. Physiological functionality of the urinary bladder may be 
impaired by aging and/or various disease states. Among them, recurrent microbial infections, 
interstitial cystitis/painful bladder syndrome, atonic or hyperactive bladder, urinary 
incontinence and cancer are prevalent debilitating pathologies that may have severe 
repercussions on homeostasis of the entire body and on life quality of the patients, also 
associated with medication5. Both systemic and topical pharmacological treatments are often 
involved, the latter offering clear advantages in terms of tolerability and efficacy due to direct 
administration of the bioactive ingredient(s) to the diseased site. This especially applies to the 
therapy of interstitial cystitis/painful bladder syndrome and cancer, which is currently carried 
out through instillation of aqueous formulations, either solutions or dispersions, via 
transurethral catheters reaching the vesical cavity from the outside3,4,11. The drug instilled, 
however, is progressively diluted because of urine collection. Besides, it is periodically washed 
out when urge to urinate can no longer be deferred in spite of the bladder being voided just 
before treatment and of concomitant restrictions on fluid intake that are generally 
recommended. The difficulties in maintaining therapeutic concentrations of bioactive 
substances within the bladder are coupled with their poor spread throughout the overlaid layers 
of the wall due to the impermeable barrier provided by the urothelium. The chances of drug 
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penetration are also limited by strict solubility, ionization, partition and molecular mass 
constraints. Furthermore, repeated and permanent use of catheters is frequently connected with 
bacterial colonization of the urinary tract and may also lead to mucosal damage, thus bringing 
about complications that would worsen the overall symptomatology and threaten the outcome 
of the therapy. Importantly, the discomfort caused by catheterization, owing to its invasive 
nature and all the drawbacks involved, is reflected in therapeutic adherence issues12,13. High 
dropout rates are indeed reported, with evil consequences especially in the case of bladder 
cancer14. This has a deep impact on healthcare costs, which is added to the burden associated 
with the dosing procedures often requiring to be performed by trained personnel. Hence, there 
is a strong rationale behind the efforts to have the residence time of drugs inside the bladder 
prolonged and improve the relevant penetration across the wall3–5,11. To these ends, several 
formulations approaches, also in combination with chemical or physical methods, have been 
explored. The most prominent strategies described in the literature range from smart hydrogel 
carriers, liposomes and nanoparticles, optionally endowed with tumor cell targeting properties, 
up to implantable indwelling devices. The latter substantially differ from therapeutic systems 
dosed as liquids via instillation in that they have own shape and macroscale dimensions. 
Moreover, once inserted into the bladder cavity, they can be retained there mainly because of 
spatial encumbrance attributes that hamper the relevant leakage with urine3,5,15. Interestingly, 
indwelling systems hold potential for yielding extended intra-organ residence and drug delivery 
over time lapses in the order of few to several days. Depending on whether or not biodegradable 
and/or bioerodible materials are used for fabrication, their elimination may either occur 
spontaneously or need to be accomplished by manual withdrawal after exhaustion16. The 
systems may alternatively be conceived in a modular form, so that smaller component units 
able to cross the urethra would be set free at the end of the drug release process17. To enable 
retention, an increase in size taking place after administration of the device, i.e. when the step 
of passing through the urethra and the bladder neck is fulfilled, has particularly been pursued. 
For instance, this has been attained by post-dose filling from the outside in the case of UROS 
oxybutynin infusion pump (Situs Co., US-CA) that was in clinical development for overactive 
bladder therapy3,18. More recently, the use of shape memory materials has been proposed as an 
attractive option to be seized4. A lidocaine-releasing intravesical system (LiRIS, TARIS 
Biomedical Inc., US-MA) has been developed for improved local treatment of interstitial 
cystitis/painful bladder syndrome19. The indwelling device is a small-sized osmotic pump 
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consisting in a two-hollow water-permeable silicone tube. One of the cavities, provided with a 
laser-drilled orifice for release, is loaded with lidocaine hydrochloride crystals, whereas the 
other one houses a wire made of superelastic nickel-titanium (nitinol) alloy. The delivery 
system is inserted into the bladder by cystoscopy while it is in an elongated shape imposed by 
the transurethral catheter. Inside the cavity, the nitinol wire switches back to a lower-energy 
coiled conformation with no sharp edges possibly harmful to the wall tissues. Shape recovery 
prevents the system from being emptied until it is non-surgically retrieved via a reverse 
cystoscopy procedure. In both female volunteers and patients, LiRIS has been successfully 
retained and well tolerated, also when administered to the healthy subjects in a placebo form 
that would rule out potentially misleading effects of the anesthetic drug20. Enduring pain relief, 
reduced voiding urgency and frequency as well as signs of bladder healing have been reported 
after a two-week treatment. With the aim of circumventing invasive removal of exhausted 
devices, the use of shape memory polymers having water solubility properties has recently been 
proposed21. Particularly, poly(vinyl alcohol) (PVA) has been selected because of its availability 
in pharmaceutical grades and water-induced shape memory effect, which could be actuated at 
body temperature. Moreover, it is a thermoplastic polymer suited for hot-processing via hot-
melt extrusion (HME) and fused deposition modeling (FDM) 3D printing22. Based on 
experience previously built in the relevant use, mainly for oral delivery targets, such techniques 
have been employed in view of the versatility they would grant in terms of achievable shapes 
and sizes for the intravesical device as well as of the interesting overall applications they may 
offer23–26. Among these, the potential of HME for continuous manufacturing and the rapid 
prototyping ability of FDM, along with its prospective use as a tool for therapy customization, 
have drawn special attention27,28. Notably, the presence of shape memory components, allowing 
morphology changes to occur upon exposure to proper external stimuli after the 3D printing 
process, has provided the basis for 4D printing, the fourth dimension lying in the time frame 
during which the programmed shape modifications would take place29,30. Prototypes conceived 
in simple original shapes have been obtained by both techniques21. Deformed to differing 
temporary shapes and immersed in distilled water at 37 °C, they have shown shape recovery as 
a function of the thermo-mechanical characteristics of the starting formulations, while releasing 
the drug tracer loaded. Feasibility of the propounded 4D printing approach to fabrication of a 
retentive delivery system has thereby been demonstrated. However, many issues are still to be 
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met, primarily including the time course of release, and extensive investigation is needed to this 
end. 
 
Gastroretentive Delivery Systems 
The stomach is a hollow muscular organ in the gastrointestinal tract, located between the 
esophagus and the small intestine. The pyloric sphincter regulates the passage of gastric 
contents (chyme) into the duodenum. The stomach is especially involved in dietary protein 
breakdown, secreting pepsinogen and hydrochloric acid that provides the acidic pH required 
for enzyme activation31,32. Fat digestion and absorption of certain substances, in addition to 
water and electrolytes, are also performed. The gastric wall consists of overlaid layers, i.e. 
mucosa, submucosa, muscularis externa and serosa, and is distensible to adapt to the contents 
that result from food and beverage ingestion as well as mucosal secretion. Accordingly, the 
stomach changes in volume from approximately 50 mL up to 1500 mL in the fasted and fed 
state, respectively6. 
Sustaining the release of drugs into the stomach has been a major goal in the field of oral 
delivery for almost five decades. Indeed, there are several compelling rationales either in 
maintaining effective gastric concentrations of therapeutic agents, for improved treatment of 
local disease conditions such as peptic ulcer, gastroesophageal reflux, Helicobacter pylori 
infection and gastritis, or in slowly supplying downstream areas of the gut with the needed 
amounts of bioactive compounds intended for systemic therapy of a range of high-prevalence 
chronic pathologies33,34. Particularly, this would apply to drug molecules that present oral 
bioavailability limitations because of a narrow upper intestinal absorption window, e.g. due to 
exploitation of carrier-mediated transport mechanisms mainly in the duodenum and jejunum. 
In addition, drugs that would poorly be stable at neutral to alkaline pH values, or may be 
degraded by intestinal digestive enzymes, may benefit from such a delivery mode. Extended 
gastric release could also provide a ploy to circumvent hurdles encountered with formulation 
of drug substances that, on account of a short elimination half-life and/or issues of peak-to-
trough fluctuations in their plasma levels, would constitute ideal candidates for administration 
as oral prolonged-release dosage forms, yet fail to meet the basic requirement of distal intestinal 
absorption. The stomach, however, poses harsh and extremely variable conditions, owing to the 
highly acidic pH and the presence of digestive enzymes as well as of food, source of possible 
detrimental drug interactions6,32. Active substances that do not present adequate solubility and 
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stability characteristics in the gastric environment, or may cause damage to the mucosal lining, 
such as typically anti-inflammatory drugs, would not be eligible for release into the stomach. 
The differing formulation strategies that have been attempted are all aimed at extended 
gastric residence of prolonged-release dosage forms, mainly encompassing mucoadhesion, 
floatation in the gastric fluid thanks to low-density or effervescence properties, high density-
induced sinking to the bottom of the stomach and expansion in volume to gain greater spatial 
encumbrance34–39. Although some have been translated into commercially-available drug 
products, particularly relying on buoyancy, each of these strategies is challenged by specific 
physiological constraints, such as mucus turnover, variable volume and viscosity of the 
contents, fluid displacement due to the subject moving and changing position, and destructive 
forces exerted by smooth muscle activity7. Overall, the above-mentioned factors strongly limit 
the possibility of achieving multi-hour gastric residence, which the organ would naturally be 
committed to prevent. This particularly relates to the fasted state, when the volume of contents 
is reduced. Even more important, rapidly successive peristaltic contractions (housekeeper 
waves) of peak intensity that come with the interdigestive migrating myoelectric complex, 
along with maximum dilation of the pyloric sphincter, lead to extensive clearance of stomach37. 
Expandable dosage forms have been recognized to offer more reliable retention chances in 
view of a greater likelihood of withstanding evacuation regardless of fasted or fed conditions, 
and of the type and amount of food ingested6,7,37. Such systems are designed to present a 
relatively small-sized initial configuration suitable for easy swallowing, and then acquire, once 
they have entered the stomach, sufficient spatial encumbrance to hamper passage through the 
wide-open pylorus. In this respect, although a broad range of dimensions have been reported, a 
cutoff of approximately 13 mm has frequently been quoted. The cumbersome configuration 
should be maintained over time to ensure retention as programmed. Finally, it should be cast 
off when drug release has been completed, to enable uncomplicated gastric emptying. Basically, 
the increase in size needed for retention has been pursued either through swelling of polymer 
components, e.g. superporous hydrogels, or unfolding of a forcedly coiled, bent or contracted 
structure. There are plenty of examples of how these concepts have been implemented, 
including proprietary Acuform (Assertio Therapeutics Inc, US-IL, formerly Depomed Inc., 
US-CA) and Accordion Pill™ (IntecPharma Inc., US-NY) technologies, respectively, that have 
yielded drug products in the marketplace or in late-stage development. Expansion-dependent 
retention tools also underlie a number of cutting-edge engineered devices, and related 
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construction materials, aimed at gastric residence times beyond 24 h up to several weeks7. Star-
shaped and spherical fenestrated structures, subject to in situ reversible expansion due to elastic 
unfolding, and a pufferfish-like hydrogel system having high-speed, high-ratio and durable 
water swelling have been described40–44. All of these would notably match the "Ultra-long-
acting oral formulation" category of FDA's Emerging Technology Program, which has been 
launched by the agency to endorse adoption of innovative pharmaceutical design and 
manufacturing schemes entailing purposely set regulatory evaluation approaches45. 
Interestingly, protracting gastric retention and release over many days or weeks would broaden 
the range of oral delivery possibilities that normally have to cope with gut transit-related 
temporal limitations7. In such cases, the dosage unit, resembling an intragastric implantable 
depot rather than a peroral modified-release formulation, could help boost adherence to chronic 
drug therapies involving multi-dose daily regimens, thus bringing social and 
pharmacoeconomic benefits, e.g. in typically non-compliant patient populations or resource-
constrained settings. 
The latest advances in the field have also relied on the use of shape memory materials, which 
hold potential for fully innovating research in the area of expandable gastroretentive delivery 
systems. Taking advantage of the superleastic properties of nitinol, previously exploited for 
LiRIS development, a device in the form of a cylindrical coil has been proposed with the aim 
of addressing compliance issues involved by long-term multi-gram daily dosing of anti-
tubercular drugs, which also raise serious drug resistance concerns46,47. Such a device is 
intended for nasogastric administration and retrieval in a straight temporary shape, as well as 
for recovery of the coiled conformation within few seconds since ejection from the dosing 
tube47. Magnets placed on either end of the metal coil would allow the system to be detected 
inside the gastric cavity and intercepted for removal after the operation time lapse. Drug 
formulations consisting in pierced vinylpolysiloxane matrix beads, containing polyethylene 
glycol as a water-soluble pore former and provided with a Eudragit RS or polycaprolactone 
coating to reduce burst effect, have been threaded on a central nitinol wire and kept in position 
by a retainer unit. Safe retention of a doxycycline hyclate-loaded prototype and sustained serum 
concentrations of the antibiotic have been demonstrated in a large swine animal model over a 
one-month period, consistent with prolonged-release in vitro results. Subsequently, nitinol has 
also been utilized for blooming flower-inspired design of an intra-esophageal device meant for 
convenient swallowing, elastic deployment within the organ cavity and consequent drug release 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
11 
 
into the mucosa through millineedles applied onto the outer surface of petal-like 
polycaprolactone arms43. Closure into a smaller-sized conformation, suitable for safe passage 
through the pylorus and intestinal tract, has been achieved by thermal triggering of shape-
memory nitinol springs upon intake of a limited volume of warm water (55 °C). 
Finally, PVA of pharmaceutical grade has been proposed for HME and FDM 3D printing of 
protoype devices having, on the one hand, a temporary configuration fitting into 00el size hard-
gelatin capsules and, on the other, a possibly retentive original shape to be recovered in the 
gastric fluid following water-induced activation of the polymer shape memory response48,49. 
Permanent shapes incorporating wide void volumes, such as S- or atom-like ones and 
cylindrical or conical coils, have been conceived and explored. Special templates, obtained by 
FDM, have been employed for manual deformation of the extruded samples to have them take 
on their temporary shapes with reduced dimensions. Irrespective of their original configuration 
and manufacturing technique, the prototypes have been shown to rapidly undergo shape 
modification in 0.1 N hydrochloric acid at 37 °C and meanwhile start releasing a drug tracer. 
Although preliminary in scope and outcome, this study has paved the way for future work, 
particularly aimed at improving the drug load and the duration of release. Thanks to the versatile 
approach used, such goals could be pursued through changes in the overall surface/volume ratio 
of the device, increased length of extruded or printed rods, application of a release-controlling 
coating and/or selection of different polymer components.  
 
Conclusions 
While so many clinical needs still fail to be met by pharmacological therapy, poor adherence 
to existing treatments of proven efficacy represents a serious hurdle to the benefits these would 
provide. Over the last decades, patient compliance issues have extensively been addressed by 
pharmaceutical formulation and drug delivery sciences, leveraging either more consolidated or 
emerging technologies. In this respect, shape memory materials are currently the subject of 
growing research interest because of the broad spectrum of exciting opportunities offered. 
Recently, their successful application to the design of drug-eluting retentive devices has been 
described, highlighting major related advantages and disclosing novel possibilities to seize. 
Thanks to the peculiar shape recovery behavior, devices based on such materials would possess 
the ability to withstand emptying from hollow organs of the body for period of times of even 
considerable duration and meanwhile release the conveyed drug in a sustained mode. The 
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urinary bladder and the stomach represent chief targets for retentive delivery systems in view 
of inherent physio-anatomic characteristics and pathological conditions they may be affected 
by. In these instances, although critical aspects associated with safety, convenience of 
administration and removal as well as duration of residence and release still require in-depth 
investigation, special benefits could be anticipated from effective combination of prolonged-
retention and prolonged-release performance. Site-selective treatments could indeed be 
performed, with a positive outcome in terms of efficacy and tolerability. In the case of 
intragastric delivery, intestinal absorption windows could also be exploited for systemic 
therapeutic purposes. Finally, medication regimens with reduced dosing frequency would be 
viable, thus prompting patient compliance in high-prevalence disease states involving direct 
and indirect costs for the healthcare systems. 
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